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Abstract: The stretch of cardiac muscle increases developed force in two phases. The first phase, which occurs rapidly, 
constitutes the well-known Frank-Starling mechanism and it is generally attributed to enhanced myofilament responsive-
ness to Ca
2+
. The second phase or slow force response (SFR) occurs gradually and is due to an increase in the calcium 
transient amplitude as a result of a stretch-triggered autocrine/paracrine mechanism. We previously showed that Ca
2+
 en-




 exchange underlies the SFR, as the final step of an autocrine/paracrine cascade involving re-




 exchanger (NHE-1) activation-mediated rise in Na
+
. In the present review 
we mainly focus on our three latest contributions to the understanding of this signalling pathway triggered by myocardial 
stretch: 1) The finding that an increased production of reactive oxygen species (ROS) from mitochondrial origin is critical 
in the activation of the NHE-1 and therefore in the genesis of the SFR; 2) the demonstration of a key role played by the 
transactivation of the epidermal growth factor receptor; and 3) the involvement of mineralocorticoid receptors (MR) acti-
vation in the stretch-triggered cascade leading to the SFR. Among these novel contributions, the critical role played by the 
MR is perhaps the most important one. This finding may conceivably provide a mechanistic explanation to the recently 
discovered strikingly beneficial effects of MR antagonism in humans with cardiac hypertrophy and failure.  







 The stretch of cardiac muscle increases developed force 
in two phases (Fig. 1). The first phase, which occurs rapidly, 
constitutes the well-known Frank-Starling mechanism and it 
is generally attributed to enhanced myofilament responsive-
ness to calcium. The second phase or slow force response 
(SFR) occurs gradually and is due to an increase in the cal-
cium transient amplitude as a result of a stretch-triggered 
autocrine/paracrine mechanism. The SFR was proposed to be 
the in vitro equivalent to the Anrep phenomenon and its 
genesis is still under debate. This is an area of research in 
which we have been working for almost the last 15 years, 
unveiling much of the components of the signalling pathway 
triggered by stretch that leads to the slow increase in contrac-
tility and very probably to cardiac hypertrophy development 
[For review see [1]]. A schematic summary of the 
autocrine/paracrine chain of events proposed by us to be 
triggered by myocardial stretch at the time when we wrote 
the first version of this review is presented in the left panel 
of (Fig. 2). Briefly, it was as follows: 1. Stretch-triggered 
release of A2/activation of AT1 receptor (AT1-R), 2. Re-
lease/formation of endothelin (ET), 3. NHE-1 hyperactivity, 
4. Increase in intracellular Na
+
 concentration, and 5. Increase  
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(NCX). In the right panel of this figure we present the recent 
advances in this particular field. Our three latest contribu-
tions to the understanding of this signalling pathway trig-
gered by myocardial stretch are:  
1) The finding that an increased production of reactive 
oxygen species (ROS) from mitochondrial origin is critical 
in the genesis of the SFR: In 2006 our group established in 
isolated cat cardiomyocytes that A2, in a concentration that 
well resembles the physiologic one, increases sarcomere 
shortening entirely through an autocrine crosstalk with en-
dogenous ET-1. Interestingly, this effect was not only ac-
companied by a rise in mitochondrial ROS production but 
also inhibited by the prevention of oxidative stress [2]. Since 
we had evidence that A2/AT1-R activation initiates the sig-
nalling pathway leading to the SFR, we hypothesized that an 
increase in ROS production could be a step in this signalling 
cascade. We certainly found that the SFR was accompanied 
by a 30% increased in ROS which promoted NHE-1 activa-
tion (Fig. 3). Supporting the notion of ROS-mediated NHE-1 
activation, we found that stretch stimulated the redox-
sensitive kinase cascade of the ERK1/2 and p90
RSK
 increas-
ing its level of phosphorylation, effect that was cancelled by 
AT1-R blockade with losartan. Moreover, scavenging the 
A2-induced ROS or inhibiting its formation prevented the 
development of the SFR [3]. We also demonstrated that 
these ROS were from mitochondrial origin but induced by a 
small amount of NADPH oxidase-derived ROS [3].  
These results were in line with previous reports 
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Fig. (1). Representative recordings of the contractile response to stretch of an isolated papillary muscle. The first increase in force (from “a” 
to “b”, top) occurs without changes in the Ca
2+
 transient (“a” to “b”, bottom) while the SFR (from “b” to “c”, top) is due to an increase in the 
amplitude of the Ca
2+
 transient (“b” to “c”, bottom). Modified from Cingolani et al. [68] with permission. 
 
 
Fig. (2). Schematic representation of the chain of events triggered by myocardial stretch that leads to the SFR and probably to cardiac hyper-
trophy and failure. The left panel depicts the state of knowledge on this subject when we wrote the first version of this review in 2007. On the 
right panel we present the recent advances in this particular field. 
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Fig. (3). A. Myocardial stretch increased intracellular ROS by ∼30 % above the baseline level, effect that was cancelled by the ROS scaven-
gers N-(2-mercaptopropionyl)-glycine (MPG) and EUK8. B. MPG and EUK8 also cancelled the SFR (expressed as percent of the initial rapid 
phase). C. Furthermore, ROS scavenging also blunted the stretch-induced increase in [Na+]i. * indicates P < 0.05 control vs. MPG and EUK8. 
Modified from Caldiz et al. [3] with permission. 
 
describing the so-called “ROS-induced ROS-release” phe-
nomenon in which NADPH oxidase-dependent O2˙ produc-
tion triggers the opening of mKATP channels, inducing mito-
chondrial depolarization and subsequent mitochondrial ROS 
generation [4-6]. 
 2) The demonstration of a key role played by the trans-
activation of the epidermal growth factor receptor (EGFR): 
The finding by Sadoshima’s group that A2, probably the 
most widely accepted hypertrophic agent, failed to induce 
cardiac hypertrophy in transgenic mice overexpressing a 
mutant AT1 receptor lacking EGFR transactivation in the 
myocardium [7], lead us to speculate that the SFR, as a result 
of the myocardial stretch-triggered signalling pathway, 
would be probably abolished by preventing EGFR transacti-
vation. This speculation was based on the concept proposed 
by us that the SFR is the mechanical counterpart of the chain 
of intracellular signals that leads to cardiac hypertrophy de-
velopment. Among the experimental evidence that support 
this last concept we should considered: 2.a. The demonstra-
tion that endogenous A2 is the initial mediator of cardio-
myocytes hypertrophy after mechanical stretch and that the 
addition of the surrounding medium of stretched myocytes 
promoted hypertrophy in non-stretched cardiomyocytes [8]; 
and 2.b. The SFR is inhibited by the selective blockade of 
AT1 receptors [9].  
 As it can be appreciated in (Fig. 4) the development of 
the SFR was blunted by different interventions that prevent 
EGFR transactivation, such as inhibition of matrix metallo-
proteinases, inhibition of Src kinase or the specific blockade 
of the EGFR, [10].  
 3) The involvement of the mineralocorticoid receptor 
(MR) in the stretch-triggered cascade: Two lines of pre-
viously existing evidence induced us to explore MR acti-
vation as a critical step in the signalling cascade leading 
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to the SFR development. 3.a. The link between A2/AT1 
receptor and the MR is an accepted fact [11-13]. 3.b. The 
fact that EGFR transactivation can be triggered by MR 
activation [11, 14, 15], and that MR-dependent increase of 
EGFR mRNA or protein expression has been reported 
[16, 17]. 
 Supporting these new lines of evidence we have demon-
strated that MR activation is necessary to promote reactive 
oxygen species formation by a physiological concentration 
of A2 (1 nmol/L) since the A2-induced production of su-
peroxide anion was abrogated when the MR was antago-
nized with spironolactone or eplerenone (Fig. 5A) [18]. 
This A2 effect was also suppressed by blocking AT1 recep-
tor, ET1 (type A) receptor or EGFR, by inhibiting NADPH 
oxidase, or by targeting mitochondria; and it was unaf-
fected by glucocorticoid receptor (GR) inhibition [18]. An 
increase in superoxide anion production promoted by an 
equipotent dose of aldosterone (ALD, 10 nmol/L) was 
blocked by spironolactone or eplerenone, by preventing 
EGFR transactivation, but not after inhibiting GR or pro-
tein synthesis, suggesting that it was the consequence of a 
non-genomic MR effect (Fig. 5B) [18]. ALD also increased 
the phosphorylation of the redox-sensitive kinases ERK1/2, 
p90RSK, and the NHE-1, effects that were eliminated by 
eplerenone or by preventing EGFR transactivation [18]. 
Finally, the SFR was suppressed by MR blockade or by 
scavenging ROS, but it was unaffected by GR blockade or 
protein synthesis inhibition as shown in (Fig. 5C). These 
results clearly suggest that MR activation is a necessary 
step in stretch-triggered mitochondrial ROS production that 
mediates the activation of redox-sensitive kinases upstream 
NHE-1, leading to the Anrep effect and also probably to 
cardiac hypertrophy development. However, a recent work 
in vivo in a transgenic mouse model of cardiomyocyte-
targeted EGFR-deficient activation while confirmed the 
critical involvement of EGFR transactivation in A2-
induced cardiac hypertrophy rejected it in cardiac hypertro-
phy due to MR activation.[19] The reason for this apparent 
discrepancy with our and others results are not clear at  
present.  
 An alternative mechanism proposed by other investiga-
tors to explain the SFR involves the stretch-activated mem-
brane channels (SACs). Myocardial stretch activates these 
non-selective cation channels, allowing Ca2+ and Na+ entry. 
The latter would then permit [Ca2+]i increase via NCX, or 
even Ca2+ entry directly augmenting the Ca2+ transient am-
plitude and driving the SFR. A role for SACs in the SFR 
was suggested by Calaghan and White in 2004 [20], mainly 
 
Fig. (4). SFR and EGFR transactivation. Panel A shows a typical force record from a cat papillary muscle subjected to stretch where it can 
be appreciated the biphasic response. Panels B-D, same as "A" but from muscles pretreated with the matrix metalloproteinase inhibitor 
(MMPI, "B"), the Src kinase inhibitor (PP1, "C") or the EGFR blocker (AG1478, "D"), interventions that cancel EGFR transactivation. As it 
can be appreciated, all these pharmacological maneuvers prevented the development of the SFR to stretch. Panel E shows the averaged re-
sults obtained under the different experimental conditions expressed as percent of the initial rapid phase. * indicates P<0.05 control curve vs. 
others (2-way ANOVA). Reproduced from Villa Abrille et al. [10] with permission. 
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as an addition to NHE1 activation in a 50-50% contribution 
manner. However, pharmacological strategies used to in-
hibit these channels were challenged based on the possible 
secondary actions of these compounds [21]. Recently, 
Ward et al. [22] reported in mouse trabeculae that opening 
of SACs appears to be the main contributor to the SFR after 
stretch. Specifically, transient receptor potential canonical 
channels (TRPC) 1 and 6 isoforms appear to be the suitable 
stretch-activated non-selective cation channels mediating 
the SFR. Interestingly, these authors inhibited the SFR us-
ing a peptide isolated from a spider venom (GsMTx-4) that 
seems to be specific to block SACs. At first glance, these 
results appear not to be in agreement with our proposal. 
However, we must consider the possibility that additional 
parallel or even in series pathways involving the aforemen-
tioned mechanisms could also exist. 
 Among our latest contributions to the understanding of 
the signalling pathway leading to the SFR the finding of a 
crucial role played by the MR was probably the most impor-
tant. This may conceivably provide a mechanistic explana-
tion to the strikingly beneficial effects of MR antagonism in 
patients with cardiac hypertrophy and failure [23-25], as it 
will be discussed latter in this review.  
 In the following sections we will focus on this steroid 
hormone receptor, its downstream signalling pathway lead-
ing to NHE-1 activation and the potential link between MR-
mediated NHE-1 activation and cardiovascular diseases.  
 
Fig. (5). Superoxide anion production induced by angiotensin II (A2). Panel A: mineralocorticoid receptor (MR) blockade with spi-
rolactone (Sp, 10 mol/L) or eplerenone (Ep, 10 mol/L) abrogated the effect of 1 nmol/L A2 on the basal rate of O2˙ production. 
This effect was also blunted by the AT1 and ETA receptor antagonists losartan (Los, 1 mol/L) and BQ123 (BQ, 10 mol/L), respec-
tively, and by NADPH oxidase inhibition with apocynin (Apo, 300 mol/L), by targeting mitochondria with 5HD (100 mol/L), 
glibenclamide (Gli, 50 mol/L), or rotenone (Rot, 10 mol/L), and by preventing EGFR activation either by EGFR blockade with 
AG1478 (AG, 1 mol/L) or by inhibiting the metalloproteinase involved in EGFR transactivation with MMPI (3 mol/L). Glucocor-
ticoid receptor inhibition with Ru-486 (10 mol/L) did not influence the effect of A2. *, p < 0.05 vs. basal O2˙ production. Panel B: 
The effect of aldosterone (ALD) at a concentration (10 nmol/L) that mimicked the effect of A2 on the basal rate of O2˙ production 
was suppressed by spirolactone (Sp) and eplerenone (Ep), but not by the glucocorticoid receptor inhibitor Ru-486 or by preventing 
protein synthesis with cycloheximide (CicHex, 7 mmol/L). This demonstrates that MR activation has nongenomic consequences and 
excludes the possibility of glucocorticoid receptor activation. On the other hand, as shown for A2, the ALD-mediated increase in ROS 
formation was prevented impeding EGFR activation (AG and MMPI). This suggests that transactivation occurs in the direction of 
activated MR to EGFR, and that metalloproteinase activation downstream of MR is crucial for EGFR transactivation. *, p < 0.05 vs. 
basal O2˙ production. Panel C: Averaged results of the SFR expressed as percentages of the initial rapid phase. MR blockade, not 
only by eplerenone but also by spironolactone, completely suppressed the SFR. However, the SFR was unaffected by the glucocorti-
coid receptor inhibitor Ru-486 or the protein synthesis inhibitor cycloheximide. Furthermore, the SFR was suppressed by the ROS 
scavenger MPG, supporting the notion that ROS formation is a key factor in the chain of events leading to the Anrep effect. Modified 
from Caldiz et al. [18] with permission. 
The Autocrine/Paracrine Loop After Myocardial Stretch  Current Cardiology Reviews, 2013, Vol. 9, No. 3     235 
ACTIVATION OF THE MR 
 The MR (or NR3C2), a member of the steroid/thyroid 
hormone receptor superfamily of ligand-inducible transcrip-
tion factors is the receptor that mediates classic ALD effects. 
This receptor family includes the glucocorticoid (GR or 
NR3C1), thyroid (THRA, THRB), retinoic acid (RARA, 
RARB, RARC), and vitamin D receptors (VDR), as well as 
several orphan receptors.  
 Although the increase in ALD concentration constitutes 
the best recognized stimulus to MR, MR can also be acti-
vated in normal or even low-ALD states [26-28]. Moreover, 
the MR was shown to have equivalent high affinity for ALD, 
cortisol (corticosterone in rodents) and DOC [29]. This is a 
relevant fact since circulating glucocorticoid levels are at 
least two orders of magnitude greater than those of ALD 
determining that MR are usually occupied, but not activated, 
by glucocorticoids (Fig. 6A). However, under pathologic 
conditions and increased oxidative stress glucocorticoids 
have been shown to activate the MR (Fig. 6B) [30].  
 In epithelial ALD-target cells the presence of the enzyme 
11-hydroxysteroid dehydrogenase (11HSD2), expressed at 
high levels, facilitates ALD occupancy and activation of the 
MR. The 11HSD2 converts active glucocorticoids (e.g. 
cortisol) into receptor-inactive 11-keto analogs (e.g. corti-
sone), significantly reducing intracellular glucocorticoid lev-
els (to ~10-fold those of ALD) [31-33] (Fig. 6C).  
 In non-epithelial tissues such as the myocardium, hippo-
campus, vascular smooth muscle and adipose tissue the ex-
pression of 11HSD2 is too low or inexistent to prevent cor-
tisol to access the MRs in competition with much lower pre-
vailing concentrations of ALD. Therefore, an unavoidable 
and yet unresolved question arises: how can aldosterone oc-
cupy and activate the MR, particularly in tissues with very 
low or no expression of the 11HSD2?  
 
Fig. (6). Schematic representation of the possible occupation of the mineralocorticoid receptor (MR) by physiological agonists. The MR has 
equivalent affinity for aldosterone (ALD) and cortisol, however circulating glucocorticoid levels are at least two orders of magnitude greater 
than those of ALD determining that MR are usually occupied, but not activated, by glucocorticoids (Panel A). Conversely, under pathologic 
conditions and increased oxidative stress glucocorticoids have been shown not only to occupy but also to activate the MR (Panel B).[30] In 
epithelial ALD-target cells the presence of the enzyme 11-hydroxysteroid dehydrogenase (11HSD2), that converts active glucocorticoids 
(e.g. cortisol) into receptor-inactive 11-keto analogs (e.g. cortisone), facilitates ALD occupancy and activation of the MR (Panel C). 
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 On the other hand the possibility exists of an ALD-
independent MR activation. Among the putative mechanisms 
of ALD-independent MR activation in the cardiovascular 
system, several possibilities should be considered: (1) Glu-
cocorticoid-mediated MR activation, especially under condi-
tions of enhanced ROS production, as reported by Mihaili-
dou et al. [30] as mentioned before (2) ligand-independent 
MR activation as the redox-sensitive Rac1-dependent activa-
tion proposed by Nagase et al. [34] (3) Direct MR phos-
phorylation independent of its own ligand, as proposed by 
Kato et al. [35] for the estrogen receptor. (4) Specific 
changes in MR conformation induced by strain, as proposed 
by Zou et al. [36] to explain AT1 receptor activation by me-
chanical stretch. 
NHE-1 STIMULATION BY MR ACTIVATION 
 Fujisawa et al. [37] demonstrated that mineralocorti-
coid/salt-induced rat cardiac fibrosis and hypertrophy was 
prevented by the selective NHE-1 blocker cariporide. It has 
also been reported that ALD up-regulates the expression and 
function of NHE-1 [38-41] and that selective blockade of 
this ion exchanger prevents and/or reverts left ventricular 
hypertrophy in various animal models [42]. According to 
these data and in agreement with our previous results on the 
SFR, we have recently shown that ALD increases NHE-1 
activity in rat ventricular myocytes through a non-genomic 
pathway (Fig. 7A) [43]. 
 As commented above, EGFR transactivation represents 
one of the signalling pathways triggered by ALD [44, 45]. It 
has been shown that the MR antagonist spironolactone re-
duces the EGFR mRNA synthesis after cerebral ischemia 
[46]. Accordingly, Grossmann et al. [45] reported that MR 
activation by ALD enhanced EGFR expression via an inter-
action with the EGFR promoter of vascular smooth muscle. 
In addition to these genomic effects, non-genomic actions of 
ALD involving EGFR transactivation have also been re-
ported [11, 47]. Consistent with this evidence, we have re-
cently shown that ALD enhances NHE-1 activity via transac-
tivation of EGFR [43]. The stimulatory effect of this hor-
mone on NHE-1 was prevented by blocking the EGFR with 
AG1478 (Fig. 7B), and also by the inhibitor of the Src-
kinase PP1 and the blocker of metalloproteinases MMPI 
[43]. These proteases release HB-EGF from its precursor, 
proHB-EGF. It has been reported that at least a fraction of 
the total amount of MR is bound to the sarcolemma, likely 
co-localized with the EGFR [14] and/or associated to caveo-
lin-1 [48]. These data would explain the binding of ALD to 
the sarcolemmal fraction reported by Le Moellic et al. [49]. 
 
Fig. (7). Aldosterone (ALD) activated the NHE-1. Panel A, top: representative traces of pHi during the application of two consecutive am-
monium pulses (20 mmol/L NH4Cl), in the absence (first pulse) and presence of 10 nmol/L ALD (second pulse). ALD was applied 10 min 
before the second pulse. Panel A bottom: average proton efflux JH, carried by the NHE-1, before (first pulses, closed circles) and after ap-
plication of 10 nmol/L ALD (second pulses, open circles). * indicates p<0.05 vs. control. Panel B top: representative traces of pHi during the 
application of two consecutive ammonium pulses (20 mmol/L NH4Cl), in the absence (first pulse) and presence of 10 nmol/L ALD (second 
pulse). AG1478 (AG, 1 mol/L) was applied 10 min before the first pulse and maintained throughout the experiment. ALD was applied 10 
min before the second pulse. Panel B bottom: average proton efflux JH, carried by the NHE-1, before (first pulses, open circles, n=4) and 
after application of 10 nmol/L ALD (second pulses, closed circles) in the continuous presence of 1 mol/L AG1478. Modified from De Gi-
usti et al. [43] with permission. 
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In addition, non genomic effects of ALD altering stimulation 
of a GPCR (GPR30) has been recently reported in vascular 
smooth muscle and endothelial cells [50]. 
POTENTIAL LINK BETWEEN MR-MEDIATED NHE-
1 ACTIVATION AND CARDIOVASCULAR DISEASE  
 Cardiovascular disease and specially heart failure is one 
of the most important health problems in the world. As de-
scribed above, cardiac hypertrophy and failure are triggered 
by intracellular signals that occur following myocardial 
stretch. Surprisingly, investigators working in the area of 
cardiac mechanics did not often extrapolate their early find-
ings seen after stretch, such as the SFR, to the development 
of cardiac hypertrophy and/or failure. The reason for this 
could be that time frames in which these two phenomena 
occur are quite different. However, the long journey toward 
myocardial hypertrophy and failure begins with one step, 
and this first step may well be the autocrine/paracrine intra-
cellular signalling pathway triggered by myocardial stretch 
as it was proposed in neonatal cardiac myocytes as well as in 
adult myocardium [3, 9, 10, 51, 52]. 
 The pathophysiological role of ALD in the development 
of cardiovascular disease has long been considered to be due 
to sodium/water retention and hypertensive effect as a con-
sequence of MR activation in renal tubular epithelial cells. 
However, recent accumulating evidence confirmed that the 
pathophysiological role of ALD is mediated not merely by 
its volume expansion/hypertensive effect, but also by its ac-
tion through MR activation in non-epithelial cells of the car-
diovascular system [23, 24, 53-55]. 
 Clinical studies demonstrated the existence of a positive 
correlation between plasma ALD levels and cardiovascular 
damage [56, 57]. Moreover, despite complete vascular ACE 
inhibition plasma aldosterone levels are elevated in patients 
with heart failure [58]. Even the combination of ACE inhibi-
tion and angiotensin II antagonism only transiently reduces 
aldosterone plasma levels in patients with heart failure sug-
gesting angiotensin II independent aldosterone production 
[59]. This phenomenon known as aldosterone escape repre-
sents a further reason to directly inhibit MR activation in 
heart failure.  
 Enhanced NHE-1 activity as a possible mechanism in-
volved in cardiac hypertrophy and failure has been reported 
in the hypertrophic myocardium of adult spontaneously hy-
pertensive rats (SHR) [60], in human ventricular myocytes 
from hearts with chronic end-stage heart failure [61], in a 
pressure-volume overload model of cardiac hypertrophy and 
failure in rabbits [62], in the hypertrophied heart of a type 2 
diabetic rat model [63] and in neonatal rats [64]. Interest-
ingly, Nakamura et al. [65] have recently demonstrated in 
vitro that NHE-1 hyperactivity is sufficient to generate cal-
cium signals required for cardiac hypertrophy to take place. 
Although in vivo physiological data supporting the involve-
ment of this mechanism in the transition to chronic cardiac 
hypertrophy and its consequences are scant, Baartscheer et 
al. [66] have shown in elegant experiments that long-term 
NHE-1 inhibition with cariporide in rabbits with combined 
pressure and volume overload cardiac hypertrophy and fail-
ure attenuated hypertrophy and decreased the previously 
augmented diastolic calcium without significant alteration of 
systolic calcium. Whether some early intracellular signals 
triggered by the autocrine/paracrine mechanism, (i.e; NHE-1 
activation) persist over time, we recently found enhanced 
oxidative stress as well as increased phosphorylation of the 
redox-sensitive p90
RSK
 kinase and NHE-1 in a mouse model 
of cardiac hypertrophy and failure promoted by transverse 
aortic constriction (TAC). Selective AT1 receptors blockade 
with losartan prevented p90
RSK
 and NHE-1 activation and 
decreased hypertrophy development, preserving contractility 
in spite of a higher workload (Fig. 8) [67]. 
 
 
Fig. (8). Schematic representation of the proposed signalling path-
way involved in the prevention of cardiac hypertrophy by AT1 
receptor blockade. In our scheme, the AT1 receptor-sensitive part 
of the transverse aortic constriction (TAC)-induced cardiac hyper-
trophy is maladaptive and related to redox-sensitive p90
RSK
 activa-
tion, NHE-1 phosphorylation/activation, increase in intracellular 
Na
+
 and the consequent increase in intracellular Ca
2+
 through the 
NCX. The increased Ca
2+
 concentration would then activate the 
calcineurin-NFAT signalling pathway responsible for triggering an 
abnormal cardiac growth. On the other hand, the same mechanical 
stimulus (stretch of cardiac muscle) may trigger other prohypertro-
phic signals intended to compensate for the increased wall stress 
("adaptive hypertrophy"). The fact that in vivo TAC-overloaded 
myocardium presents increased NHE-1 activity (evidenced by the 
increase in NHE-1.and p90
RSK 
phosphorylation), supports that the 
stretch-induced activation of the exchanger detected in in vitro ex-
periments persists after 7 weeks and it is able to be blunted by AT1 
receptor blockade. Considering that A2 probably induces the activa-
tion of the myocardial MR, a contribution of the activation of this 
latter receptor to the development of inappropriate hypertrophy 
should be considered. Modified from Cingolani et al. [67] with 
permission. 
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FACTS AND PERSPECTIVES IN HEART FAILURE 
TREATMENT  
 Current treatment against cardiac failure is mainly based 
on inhibition of hormones (A2, ALD, catecholamines). De-
spite the term “ALD inhibition” has been widespread used, 
this is often misleading and should be replaced by MR an-
tagonism, mainly because ALD is not the only agonist bind-
ing to and activating MR as mentioned before [30]. Although 
several studies have demonstrated the important benefits of 
MR antagonists in heart failure, their clinical use remains 
lower than expected and the exact mechanism of the benefi-
cial effect is still unknown. 
 Among MR inhibitors, spironolactone was the first mar-
keted compound in the early 1960s, and although proved to 
be clinically useful, it also showed tolerability problems. 
Nevertheless, it was the only compound approved to be used 
in the RALES in patients with severe heart failure (Class III-
IV NYHA). The trial was terminated prematurely due to an 
interim analysis revealing a ~30% reduction in the relative 
risk of death in spironolactone-treated patients [24]. There 
was an equal and impressive reduction in hospitalization for 
cardiac reasons. Later on, more specific MR antagonists 
were developed and clinically tested. The EPHESUS clinical 
trial was performed on 6642 patients with acute myocardial 
infarction complicated with left ventricular systolic dysfunc-
tion. Treatment started 3 to 14 days after myocardial infarc-
tion and was maintained during 16 months. All cause mortal-
ity decreased by ~15% and sudden cardiac death by ~21 % 
in the eplerenone-treated arm [23].  
 Contrasting with the two above-mentioned clinical trials, 
the recently published EMPHASIS [25] was carried out on 
patients with less severe heart failure. This study enrolled 
2737 patients with heart failure class II and III of the NYHA 
and left ventricular ejection fraction of no more than 35 %. 
The trial was stopped prematurely after a median follow-up 
of 21 months, due to the excess of benefit in reducing the 
risk of cardiovascular death or hospitalization for heart fail-
ure, obtained by anti-aldosteronic therapy with eplerenone, 
which was then extended to both arms of the trail. 
 Although clinical evidence undoubtedly showed benefi-
cial effects of treating heart failure patients with MR block-
ers, the mechanisms by which MR antagonism provide car-
diovascular protection are not completely understood. In this 
regard, our own results assigning a crucial role for MR acti-
vation as an early hypertrophic signal triggered by myocar-
dial stretch encouraged us to suggest that prevention of oxi-
dative stress and NHE-1 activation should be considered as a 
potential key factor for the salutary effects of ALD antago-
nism in humans. 
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